There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Taysha Gene Therapies (TSHA – Research Report), Biogen (BIIB – Research Report) and Regeneron (REGN – Research Report) with bullish sentiments.
Taysha Gene Therapies (TSHA)
Piper Sandler analyst Christopher Raymond maintained a Buy rating on Taysha Gene Therapies today and set a price target of $9.00. The company’s shares closed last Tuesday at $2.57.
According to TipRanks.com, Raymond is a 4-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Taysha Gene Therapies with a $7.17 average price target, a 160.7% upside from current levels. In a report released yesterday, Jefferies also upgraded the stock to Buy with a $8.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Biogen (BIIB)
Jefferies analyst Michael Yee maintained a Buy rating on Biogen today and set a price target of $285.00. The company’s shares closed last Tuesday at $226.88.
According to TipRanks.com, Yee is a 2-star analyst with an average return of
Biogen has an analyst consensus of Strong Buy, with a price target consensus of $289.57, a 28.1% upside from current levels. In a report issued on May 3, HSBC also maintained a Buy rating on the stock with a $342.00 price target.
Regeneron (REGN)
Jefferies analyst Akash Tewari maintained a Buy rating on Regeneron yesterday and set a price target of $1060.00. The company’s shares closed last Tuesday at $984.64, close to its 52-week high of $998.33.
According to TipRanks.com, Tewari is a 5-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Regeneron with a $1055.94 average price target, which is a 7.7% upside from current levels. In a report issued on May 2, Wells Fargo also maintained a Buy rating on the stock with a $1050.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on TSHA:
- Taysha Gene Therapies Reports First Quarter 2024 Financial Results and Provides Corporate Update
- Taysha Gene Therapies assumed at Buy from Hold at Jefferies
- TSHA Upcoming Earnings Report: What to Expect?
- Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Taysha Gene Therapies announces RMAT designation granted to TSHA-102 by FDA
